Aspen Pharmacare Holdings Limited (APNHY)
Data as of Nov 2, 3:58 PM ETPrices may be delayedHow our data works
Res / Sup are automatic swing levels for educational reference only — not signals or advice.
Prices may be delayed. For informational purposes only — not investment advice.
APNHY key stats
APNHY GlowScore: Quiet
A 0–100 read on today's activity from volume, momentum and intraday range. Not a buy or sell signal.
About Aspen Pharmacare Holdings Limited
ASPEN PHARMACRE HL UN/ADR
What's moving APNHY today
Updated November 3, 2026As of November 3, 2026, Aspen Pharmacare Holdings Limited (APNHY) stock edged higher to $9.66, up 0.31% (+$0.03) versus the previous close. That puts APNHY near the top of its 52-week range of $5.25 to $10.05. Roughly 1 shares have changed hands so far.
Latest APNHY news
- Is Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?Yahoo Finance· Nov 2, 8:40 AM ETAVAH
- Are Medical Stocks Lagging Aspen Pharmacare (APNHY) This Year?Yahoo Finance· Oct 15, 8:40 AM ETCORT
- Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?Yahoo Finance· Sep 29, 8:40 AM ETCORT
- Aspen Pharmacare Holdings Ltd (APNHF) (FY 2026) Earnings Call Highlights: NHEPS Surges 28% as ...Yahoo Finance· Sep 3, 5:00 PM ETAPNHF
- Aspen Pharmacare Canada receives Health Canada approval for a generic equivalent of Ozempic®Yahoo Finance· Jul 21, 10:45 AM ET
- Aspen Pharmacare Holdings Insider Ups Holding During YearYahoo Finance· Apr 3, 3:42 AM ET
- Aspen Shares Surge on $1.6 Billion Asia-Pacific Asset SaleYahoo Finance· Dec 29, 9:55 AM ET
Source: Yahoo Finance RSS · Updated November 3, 2026
Want APNHY headlines, alerts and AI research in one place? Create a free account →
APNHY Congress & insider trades
Congress amounts are the disclosed ranges; filings can lag the trade date by up to 45 days.
AI research on APNHY
Get an instant AI breakdown of the bull & bear case, key risks, and what analysts are watching.
Not financial advice. This page is for educational purposes only. Data comes from third-party sources, may be delayed or incomplete, and should not be the basis of any investment decision.